Vertex Pharmaceuticals (VRTX) Operating Income (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Operating Income of $1.1 billion for Q1 2026, up 80.62% year-over-year from $630.1 million in Q1 2025, and down 5.62% quarter-over-quarter from $1.2 billion in Q4 2025.
Vertex Pharmaceuticals (VRTX) Operating Income (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Operating Income history runs 18 years deep, the most recent figure standing at $1.1 billion for Q1 2026.
- In Q1 2026, Operating Income rose 80.62% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $4.7 billion (up 730.65% YoY), while the FY2025 annual figure was $4.2 billion, up 1891.88% from the prior year.
- Operating Income for Q1 2026 stood at $1.1 billion, down from $1.2 billion in the prior quarter.
- The five-year high for Operating Income was $1.2 billion in Q4 2025, with the low at -$3.5 billion in Q2 2024.
- The 5-year median for Operating Income is $1.0 billion (2022), against an average of $777.5 million.
- The sharpest annual moves came in 2022 and 2024: Operating Income surged 3019.0% in 2022, then sank 442.43% in 2024.
- Vertex Pharmaceuticals' Operating Income stood at $1.0 billion in 2022, then dropped by 4.35% to $988.5 million in 2023, then increased by 3.79% to $1.0 billion in 2024, then climbed by 17.53% to $1.2 billion in 2025, then slipped by 5.62% to $1.1 billion in 2026.
- Business Quant data shows VRTX's Operating Income at $1.1 billion in Q1 2026, $1.2 billion in Q4 2025, and $1.2 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -365.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.25 Bn |
| Mar 31, 2026 | 1.14 Bn |
| Dec 31, 2025 | 1.21 Bn |
| Sep 30, 2025 | 1.19 Bn |
| Jun 30, 2025 | 1.15 Bn |
| Mar 31, 2025 | 630.10 Mn |
| Dec 31, 2024 | 1.03 Bn |
| Sep 30, 2024 | 1.12 Bn |
| Jun 30, 2024 | -3.51 Bn |
| Mar 31, 2024 | 1.14 Bn |
| Dec 31, 2023 | 988.50 Mn |
| Sep 30, 2023 | 1.04 Bn |
| Jun 30, 2023 | 1.03 Bn |
| Mar 31, 2023 | 779.00 Mn |
| Dec 31, 2022 | 1.03 Bn |
| Sep 30, 2022 | 1.13 Bn |
| Jun 30, 2022 | 1.11 Bn |
| Mar 31, 2022 | 1.04 Bn |
| Dec 31, 2021 | 877.70 Mn |
| Sep 30, 2021 | 1.05 Bn |